GSK and Flagship Pioneering have entered into a partnership worth up to $7bn to discover and develop novel medicines and vaccines for a range of conditions.
Bringing together GSK’s expertise in disease and development capability via Flagship’s ecosystem of bioplatform companies, the collaboration aims to develop a portfolio of up to ten future medicines and vaccines, beginning in respiratory and immunology, which will each be subject to an exclusive option by GSK for further clinical development.
As part of the deal, both companies will initially fund up to $150m upfront to support an exploration phase to identify the most promising concepts for further research and development utilising Flagship’s bioplatform companies, which will be eligible to receive up to $720m in upfront, development and commercial milestones from GSK, as well as preclinical funding for each acquired programme plus tiered royalties.
Commenting on the collaboration, GSK’s chief scientific officer, Tony Wood, said: “We look forward to partnering with… Flagship and [its] ecosystem of bioplatform companies to further accelerate our pipeline and discover practice-changing medicines and vaccines for patients.”
Paul Biondi, general partner, Flagship and president, Pioneering Medicines, commented: “This collaboration is the latest example of Flagship’s Innovation Supply Chain Partnership model, which is designed to generate transformational medicines together with our pharma partners… to create a sustainable source of treatments for patients with the greatest unmet needs.”
Click here to continue reading.